The implantable cardioverter-defibrillator (ICD) is a life-saving therapy in patients with hypertrophic cardiomyopathy (HCM) at high risk of sudden cardiac death. The heterogeneity of clinical scenarios in HCM and the availability of ICDs with distinct characteristics emphasizes the need for selecting the right device for the right patient. There is growing awareness that unnecessarily complex devices can lead to short- and long-term complications without adding significant clinical benefits. Young patients have the greatest potential years of life gained from the ICD but are also most exposed to device-related complications. This increases the complexity of decision-making of ICD prescription in these often otherwise well patients in whom device selection should be tailored to preserve survival benefit without introducing morbidity. In the light of the multiple clinical phenotypes characterizing HCM, the present article offers evidence-based perspectives helpful in predicting the individual impact of the ICD and choosing the most appropriate device.

Implantable cardioverter-defibrillators for hypertrophic cardiomyopathy: the times they are a-Changin' / Francia, Pietro; Olivotto, Iacopo; Lambiase, Pier D; Autore, Camillo. - In: EUROPACE. - ISSN 1099-5129. - (2021), pp. 1-11. [10.1093/europace/euab309]

Implantable cardioverter-defibrillators for hypertrophic cardiomyopathy: the times they are a-Changin'

Francia, Pietro;Autore, Camillo
2021

Abstract

The implantable cardioverter-defibrillator (ICD) is a life-saving therapy in patients with hypertrophic cardiomyopathy (HCM) at high risk of sudden cardiac death. The heterogeneity of clinical scenarios in HCM and the availability of ICDs with distinct characteristics emphasizes the need for selecting the right device for the right patient. There is growing awareness that unnecessarily complex devices can lead to short- and long-term complications without adding significant clinical benefits. Young patients have the greatest potential years of life gained from the ICD but are also most exposed to device-related complications. This increases the complexity of decision-making of ICD prescription in these often otherwise well patients in whom device selection should be tailored to preserve survival benefit without introducing morbidity. In the light of the multiple clinical phenotypes characterizing HCM, the present article offers evidence-based perspectives helpful in predicting the individual impact of the ICD and choosing the most appropriate device.
2021
hypertrophic cardiomyopathy; implantable cardioverter-defibrillator; sudden cardiac death
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Implantable cardioverter-defibrillators for hypertrophic cardiomyopathy: the times they are a-Changin' / Francia, Pietro; Olivotto, Iacopo; Lambiase, Pier D; Autore, Camillo. - In: EUROPACE. - ISSN 1099-5129. - (2021), pp. 1-11. [10.1093/europace/euab309]
File allegati a questo prodotto
File Dimensione Formato  
Francia_Implantable_2021.pdf

solo gestori archivio

Note: review
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.4 MB
Formato Adobe PDF
1.4 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1655490
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact